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1. Introduction
1.1. Hepatitis C is curable now
Since its discovery in 1989, hepatitis C virus (HCV) infection always remained a big challenge 
for the physicians, clinicians, and healthcare providers to treat as well as for the scientists 
and researchers to design and develop novel compounds to inhibit viral replication and 
polyprotein processing. The classical treatment by interferon therapy as once known as the 
“gold standard of care” was not so much effective in different HCV genotype (GT)-treated 
patients, and treatment-emergent adverse events were generally a potential reason of treat-
ment discontinuation [1]. The addition of ribavirin (RBV) to pegylated interferon (PEG-IFN) 
raised the hopes to achieve high cure rates; however, dual therapy was successful 70–80% in 
HCV GT 3 and only 50–60% in HCV GT 1- and GT 2-infected patients. In that era, the ample 
understanding of HCV life cycle, better understanding of pathophysiology of the disease, and 
the emergence of new technologies urged the researchers to develop novel compounds which 
directly target to different parts of the HCV genome which are essential components of viral 
replication and polyprotein processing [1].
1.2. Novel treatment options on the horizon
The landscape in hepatitis C medicine started to revolutionize from 2011, when the first 
time direct-acting antivirals (DAAs) were administered to hepatitis C virus-infected 
patients along with PEG-IFN and RBV [1]. After that, the advent and approval of different 
DAA combination have shifted the treatment paradigms for all seven HCV GT-infected 
patients and even difficult-to-treat-specific populations (HCV GT 1a- and GT 3-infected 
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individuals, cirrhotic patients, HCV/HIV coinfection, severe renal impairment and liver 
transplant, and previous treatment failure with NS3/4A or NS5A inhibitors). By inhibiting 
viral replication and blocking polyprotein processing, these novel and innovative DAAs 
are categorized into four groups, namely, nucleoside RNA-dependent RNA polymerase 
(RdRp; NS5B protein) inhibitors (NIs), non-nucleoside RdRp inhibitors (NNIs), viral rep-
lication complex inhibitors (i.e., NS5A protein), and viral serine protease (i.e., NS3/4A 
protein) inhibitors (PIs) [1]. Interestingly, the treatment regimens achieve higher sustained 
virologic response rates (SVR; HCV viral RNA undetectable at the end of week 12) only 
when used in combination as dual or triple therapeutic regimens, and single DAA therapy 
is either not so much effective or recommended to use [2]. Some DAAs have been developed 
as a single pill of fixed dose combination (FDC) of two, three, or even more compounds, and 
all DAAs are given orally to infected patients. The use of RBV is still considered an integral 
part of some DAAs while considering certain complicated hepatitis C patient populations 
including HCV cirrhotic patients; treatment-experienced patients with PEG-IFN, PEG-IFN/
RBV, and first-generation PIs (telaprevir, boceprevir); and patients with decompensated 
cirrhosis. In parallel to that, the treatment strategies, dosage frequencies, and treatment 
duration vary for different HCV GTs and harder-to-treat-specific patient populations (e.g., 
HCV GT 3-infected patients; HCV patients with compensated/decompensated cirrhosis; 
previous treatment failure with PEG-IFN/RBV, first-generation PIs, and NS5A inhibitors; 
HCV/HIV coinfection; and patient with liver transplant or severe renal impairment). Some 
treatment options with pan-genotypic HCV coverage have been approved by the Food and 
Drug Administration (FDA) of the United States of America (USA), and some are in the final 
stage of development. Some different antivirals with an alternate mechanism of action such 
as by inhibiting viral entry or cell-to-cell spread and some anti-mRNA-based strategies like 
microRNAs are also in the pipeline [1, 2].
1.3. The treatment for hepatitis C is remarkably effective but with caveat
The clinicians, seeing outcomes they never thought possible, and experts are optimistic that 
more complex and challenging patients will respond to therapy. It has amalgamated the 
efforts to purge the viral scourges, to cure the infection, and to accomplish the potential global 
goal of HCV eradication. However, treatment choices can be tricky, and caveats are emerging 
including the recurrence of liver cancer and hepatitis B reactivation in chronically infected 
HCV or difficult-to-treat individuals. Equivocally, several important issues prevail linking 
to disease prevalence, viral screening, therapy adherence, reinfection, drug costs, expansion 
of care domain, and emergence of resistance-associated substitutions (RASs) in hepatitis C 
populations. Despite the incredible evolution in HCV therapeutics, much remains to be done 
to the point where it is a minimal entity. Now is the provident time to carefully consider 
population-level priorities and engineer HCV treatment strategies along with health policies 
which are realistic vis-à-vis implementation at a national or even pan-national level.
This book intends to comprehensively discuss hepatitis C virus infection progression, associ-
ated HCV clinical implications, and revolutionary anti-hepatitis C regimens and lends crucial 
insights on the opportunities that new therapies will bring to eliminate this silent but curable 
disease. It is not possible to discuss here HCV pathophysiology and therapeutics in detail, 
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but our intentions and aims in the introductory book chapter (Chapter 1) and the whole book 
itself are very clear: to provide general but valuable information from a common reader to an 
HCV specialist as well as to sketch a complete landscape of hepatitis C from infection to cure.
2. HCV disease progression
Afflicting around 170 million people worldwide [1], HCV infection is the foremost cause of 
liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC) and the first reason for liver 
transplantation [3]. The propagation of hepatitis C from acute to chronic infection and after-
ward to end-stage liver diseases involves a highly orchestrated series of molecular and cellular 
events including a plethora of genes and cell signaling cascades. The acute phase of infection is 
frequently asymptomatic or associated with mild and nonspecific symptoms. Persistent HCV 
infection is one of the major causes of chronic liver disease in 80% of infected individuals [4]. 
Approximately 20% of chronic carriers may develop liver cirrhosis, and some of these cases will 
progress to hepatocellular carcinoma (HCC). Consequently, HCV-induced chronic liver dis-
ease is recognized as the leading indication for orthotopic liver transplantation [5]. The studies 
 demonstrate that HCV-induced inflammatory responses use host responses to recruit inflam-
matory cells and further prime a coordinated event of several host protein-protein interactions 
[4, 5]. Chapter 2 of this book highlights the recent advances in HCV-induced inflammatory 
responses and the role of inflammation during HCV infection. In addition, HCV affects other 
body cells including the immune system cells, and this ability of HCV to disrupt immune cells is 
evident to cause occult infection (e.g., mixed cryoglobulinemia and B-cell non-Hodgkin’s lym-
phoma) [6]. How HCV lymphotropism affects the function of immune cells, virus persistence, 
and immune cell proliferation are discussed in Chapter 3. It is also believed that the progression 
of HCV to hepatocellular carcinoma (HCC) involved DNA methylation of cancer-related genes 
[7]. Chapter 4 illustrates how the detection of such genes may be helpful to know the different 
stages of disease progression from hepatitis C to HCC. In the setting of HCV infection, the 
role of various microRNAs (miRNAs) in modulating viral infection response has been deeply 
studied that clarifies causes of chronic hepatitis C progression in most infected patients and 
consequences of infection with manipulation in the risk of developing HCV-related comorbidi-
ties (i.e., cirrhosis and hepatocellular carcinoma) [8]. miRNAs are a class of small, endogenous, 
conserved, noncoding RNAs with a length of 20–24 nucleotides which posttranscriptionally 
regulate target genes. miRNA are also proved as key regulators of homeostasis for multiple 
biological systems, besides modulation of the disease pathology of many cancers. Similarly, 
miRNAs act as key modulators of HCV and hepatitis B virus (HBV) infection and liver disease 
progression [8]. Chapter 5 elaborates the regulation of miRNAs in HCC-related HCV patients.
3. HCV-associated clinical implications
Metabolic syndrome, obesity, and insulin resistance are very common health problems around 
the world with an increased morbidity rate. These comorbidities further contribute to hepatic 
steatosis, which ultimately lead to fat deposition in the liver [9]. Some studies predict that 
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these pathological states may limit response to IFN-based treatment regimens while treating 
hepatitis C; however, interestingly therapeutic response is not impaired to DAAs [10]. Now 
with curative treatment options available for patients with HCV, the sequelae of steatosis, 
fibrosis, and its drivers will garner more attention. Several other metabolic factors (e.g., vita-
min D) could be related to more liver damage and high degree of fibrosis [9, 10]. In Chapter 
6, Prof. Villar reviews the challenges and metabolic pathology associated with HCV infection 
and highlights some metabolic factors with their significant impact on liver damage. Several 
studies demonstrate that HCV infects other body organs and clinical implications may be 
very serious in chronically infected HCV patients. Some clinical studies suggest the associa-
tion of HCV for the onset of periodontal disease in infected individuals [11]. The connection 
such connections between periodontal disease and hepatitis C must be considered by rel-
evant healthcare practitioners due to their important implications on clinical manifestations 
and treatment strategies. Prof. Surlin Petra describes an update on periodontal implication 
of hepatitis C infection in Chapter 7. In addition to that, epigenetic modulation during HCV 
infection progression may also contribute to the development of HCV-related liver diseases 
(e.g., hepatic fibrosis and hepatocarcinogenesis) [12]. Chapter 8 describes the host and viral 
factors associated with the progression of hepatic fibrosis in HCV-infected individuals.
4. Current treatment landscape
4.1. The new HCV drugs are considered revolutionary
Treatment of chronic hepatitis C has markedly been improved with the introduction of IFN-
free DAA therapies since 2011. New DAAs for chronic hepatitis C can cure infection in more 
than 95% of patients. Greater provision of DAAs, as well as greater efficacy of these medica-
tions in recent years, has led to a steady increase in SVR rates in HCV patients. The big picture 
is one of the clinical successes where we know that 95–100% of patients treated for hepatitis C 
can be cured [13]. It is pretty amazing.
The currently available DAAs are based on their target site with a particular mechanism of 
action [1, 2, 13]. NS3-4A serine protease inhibitors (NS3-4A PIs) block posttranslational pro-
cessing of viral polyproteins by binding to the catalytic site of the enzyme which prevent 
the release of functional, nonstructural proteins. The first-generation PIs (i.e., telaprevir and 
boceprevir) were recommended for HCV GT 1-infected patients in 2011 in combination with 
PEG-IFN and RBV as a triple regimen with estimated SVR rates between 65 and 80%. However, 
the treatment-emergent adverse events, potential drug-drug interactions, essential necessity 
of PEG-IFN, and low genetic barrier to drug resistance were the major disadvantages associ-
ated with these drugs. Consequently these regimens are not recommended to treat hepatitis C 
and were discontinued. The landmark era in HCV therapeutics was started in December 2013 
when the first IFN-free all-oral regimen, an NI inhibitor (sofosbuvir) also known as “Magic 
bullet,” was approved for hepatitis C treatment [13]. The SVR rates achieved were more than 
90%, and the regimen was considered safe, with fewer drug-drug interactions, very low 
adverse event profile, superior SVR rates, and an ability to use in combination with other regi-
mens to treat difficult HCV populations with satisfactory therapeutic outcomes. After that a 
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series of innovative DAAs have been approved by the US FDA to treat hepatitis C with excel-
lent SVR rates. The second-generation DAAs in combination are highly effective to treat the 
wide spectrum of HCV populations, and some have shown clinical promise as pan-genotypic 
and panfibrotypic coverages [2, 13]. The first-generation PIs include telaprevir (TVR) and 
boceprevir (BOC), while second-generation PIs include simeprevir (SMV), ritonavir-boosted 
paritaprevir (PTV), asunaprevir (ASV), grazoprevir (GZR), voxilaprevir (VOX), and glecap-
revir (GLE). NS5A inhibitors block their regulation capability of viral replication within the 
replication complex and also inhibit the viral assembly and release. First-generation NS5A 
inhibitors include daclatasvir (DCV), ledipasvir (LDV), ombitasvir (OBV), and elbasvir (EBR), 
while velpatasvir (VEL) and pibrentasvir (PIB) are categorized into second- or next-generation 
NS5A inhibitors. NNIs bind to one of the four allosteric sites of RdRp and block the catalytic 
function of RdRp which indirectly block RNA replication. Dasabuvir (DSV) is the only FDA-
approved NNI, which is used in combination with other DAAs to treat hepatitis C. NIs act as 
a false substrate for HCV RNA polymerase enzyme during viral replication where its incor-
poration results in chain termination during viral RNA synthesis. Sofosbuvir (SOF) is the 
sole example in this category of IFN-free DAA regimens. However, SOF sets a new standard 
of care for HCV patients as it is used in combination with other DAAs for the treatment of 
almost all HCV GT patients and even difficult-to-treat-specific populations [1, 2, 13].
4.2. Pan-genotypic regimens
Until now, the US FDA has approved three pan-genotypic DAA combination regimens to 
treat HCV GT 1–6 and even difficult-to-treat-specific populations. The first pan-genotypic 
combination regimen including SOF and VEL (Epclusa®) as a FDC of single pill for 12 weeks 
is recommended for GT 1–6 patients without cirrhosis or with compensated cirrhosis. The 
regimen is also administered to patients with decompensated cirrhosis; however, in this case 
RBV is added to active regimens [2]. In July 2017, the US FDA approved Vosevi® (SOF/VEL/
VOX) to treat adults with chronic hepatitis C GT 1 to 6 without cirrhosis or with mild cirrhosis 
[14]. Vosevi® is a once-daily single tablet that contains two previously approved drugs—the 
NIs SOF (400 mg) and NS5A inhibitor VEL (100 mg)—and the newly approved pan-genotypic 
PIs VOX (100 mg). Vosevi® is the first FDA-approved treatment for patients who have been 
previously treated with the DAAs SOF or other drugs for HCV that inhibit NS5A. SVR12 was 
achieved in more than 90% of patients after the end of treatment [14]. In August 2017, the 
US FDA approved the combination of GLE and PIB (Maviret®) for the treatment of chronic 
hepatitis C for adults with chronic HCV GT 1 to 6 without cirrhosis or with mild cirrhosis 
including those with moderate to severe kidney disease and those on dialysis [15]. It is also 
indicated for adults infected with HCV GT 1 who were previously treated with either an 
NS5A inhibitor or an NS3/4A PIs, but not both. The drug reduces by 4 weeks the time needed 
for a cure by administering once daily as three oral tablets. The treatment regimen for GLE/
PIB lasts 8 weeks, while the standard treatment length previously was at least 12 weeks for 
other DAA combinations. The combination GLE/PIB is also effective for treating HCV infec-
tion in individuals coinfected with HIV-1, according to results from the non-randomized, 
open-label phase III clinical trials [16]. Both Vosevi® and Maviret® are active against all HCV 
GTs, and with little differences, the two medicines may be specifically useful in some harder-
to-treat-specific populations or those who failed or cannot use previously available therapies 
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[14–16]. In Chapter 9, Prof. Sidra discusses the safety, tolerability, and associated side effects 
of DAAs emphasizing their clinical pharmacology as well as the important safety issues of 
drug-drug interactions (DDIs). Similarly, Prof. Tran in Chapter 10 overviews a mathematical 
model while using sensitivity and identifiability techniques to determine model parameters 
in hepatitis C viral dynamics using a combination therapy of IFN, RBV, and TVR for partial 
viral response, sustained viral response, and breakthrough patients.
4.3. Emerging anti-HCV regimens
An 8-week regimen containing grazoprevir-ruzasvir-uprifosbuvir appears to be effective 
for treating hepatitis C virus infection in patients with or without cirrhosis, according 
to findings from a pair of randomized phase II open-label trials [17]. SVR12 rates with 
8 weeks of therapy were 93% in individuals with GT 1a, 98% with GT 1b, 86% with GT 2 
(without cirrhosis, patients with HCV GT 2 and cirrhosis received a longer course), 95% 
with GT 3 (treatment naive, without cirrhosis), and 100% with GT 4 and 6. Interestingly, 
the 8-week duration of therapy for HCV GT 2 patients achieved lower cure rates; however, 
treatment extension to 12 weeks overcame this effect. The excellent treatment outcomes in 
phase II clinical trials support further investigation of grazoprevir, ruzasvir, and uprifos-
buvir as a pan-genotypic regimen in phase III clinical trials, where this combination has 
the potential to provide a safe, single-duration regimen for HCV patients with and with-
out cirrhosis including harder-to-treat GT 3 individuals who had previously treated with 
PEG-IFN and RBV. The clinicians are also hopeful that excellent therapeutic outcomes of 
such regimens in ongoing phase III clinical trials will provide safer options with regard 
to pan-genotypic regimens for the treatment of hepatitis C and may impact the current 
treatment landscape [17].
5. Challenges for new regimens
The advancement in HCV therapeutics is fabulous and trustworthy after the introduction 
of well-tolerated and safe oral interferon-free DAAs in treatment strategies which provides 
compassionate treatment for HCV-infected patients to get cured and back to normal life. 
However, the next frontiers in front of researchers and clinicians are to coup certain chal-
lenges which may interrupt to achieve high cure rates in treated individuals and may be 
a potential cause of suboptimal SVR rates in difficult-to-treat subpopulations in real-world 
clinical practice. Until now, the real-world clinical data is not so much largely published/
produced to make a clear understanding and interpretation of these obstacles; however, the 
treatment costs, risks of HBV reactivation and liver cancer recurrence, and the emergence of 
resistance-associated substitutions (RAS) are potential barriers which may prevent to achieve 
the global goal of HCV eradication [2]. Likewise, the dosage algorithms and safety profiles of 
such regimens in patients under age 18, in pregnant females, and end-stage liver disease and 
post-transplant patients are yet to be extensively elucidated [2]. The following section briefly 
overviews these harboring issues with some supporting clinically published data and also 
suggests some possible solutions in this prospect.
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5.1. Drug costs and treatment access
The high therapy cost in the developing world or even in resource-replete nations and lack of 
treatment access in some areas where HCV is highly prevalent (e.g., in Egypt and some part 
of South Asia, where HCV is endemic) are major limitations of current anti-hepatitis C regi-
mens [2]. An average treatment cost may be from 65,000 to 110,000 USD when brand-name 
therapies are administered to HCV-infected patients for a 12-week duration. Is it splurging at 
these prices to cure hepatitis C? The answer is certainly no. In the USA, most of the insurance 
companies have adopted a policy of “prioritizing coverage to those who need it the most,” 
and some states are authorizing the treatment while using the extent of a patient’s hepatic 
fibrosis (stage 3 or 4) or cirrhosis to cover the cost of HCV drugs. In some states, the deci-
sion is usually left to third-party payers. In Europe, the healthcare policy frequently bases 
the administration of hepatitis C therapy on fibrosis stage, so the patients with later-stage 
disease are often given preference. Although the use of HCV generics cut the cost as first data 
are encouraging in clinical studies, it is too early to comment on the clinical efficacy of these 
regimens, and the emergence of adverse events in treated individuals is not fully elucidated, 
and studies are going on. The brand-name drugs are comparatively cheaper in Europe than 
in the USA but still much expensive in India. The generic drug costs should be even lower 
to provide these regimens to individuals who need it the most. Such treatment with mini-
mal diagnostic support is urgently required in low- and middle-income countries (12 out of 
20 countries with the highest ratio of HCV prevalence are classified as low or lower-middle 
income) where treatment access is extremely limited due to high drug costs and complexity of 
patient management. In such areas, “test-and-treat strategies” and “risk-stratified approach” 
could be implicated to provide a targeted therapy for patients with high risks of HCV pro-
gression. In this context, risk prediction tools may help the physicians and patients to decide 
whether to initiate the treatment with costly DAAs or to sustain affordable treatment even 
with PEG-IFN and RBV to achieve high SVR rates [2].
5.2. HBV reactivation risk with DAAs
Patients with a past or current HBV infection can experience sometimes fatal HBV reactiva-
tion if they take any of 11 approved DAAs for hepatitis C virus (HCV) infection treatment 
[18]. The US FDA recommends a box warning for the drugs advising clinicians to screen 
patients for evidence of a past or current HBV infection before ordering antiviral treatment for 
HCV. The FDA identified 24 cases of HBV reactivation in coinfected patients treated with these 
antivirals from November 22, 2013, to July 18, 2016, in reports to the agency and published lit-
erature. Two patients died, and one needed a liver transplant. Interestingly, clinical trials for 
the HCV drugs in question/approval did not report HBV reactivation because they excluded 
patients infected with HBV and it was not reported as an adverse event in phase III clinical 
trials for the DAAs’ approval. Similarly, such exclusion characterizes higher DAA safety, in 
terms of potential liver adverse reactions in the presence of one virus infection (i.e., HCV) 
instead of conducting more complicated safety evaluation of DAAs in patients infected with 
both HBV and HCV. The exact mechanism of HBV reactivation is still not known; however, 
it is considered that it may result from a complex interplay of host immunologic responses 
in the setting of infection with two hepatitis viruses. It is also assumed that HBV reactivation 
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may result from HCV clearance rather than a drug-specific toxicity. The treatment-induced 
reduction in HCV by DAAs also suppresses HBV, and the lack of activity against HBV of 
DAAs plus immunologic responses may escape HBV to reactivate [18].
Flare-ups of inactive or once-resolved HBV with DAAs have rung alarm bells before. In 
March 2016, the European Medicines Agency (EMA) announced that it had launched a review 
of six DAAs for HCV on the basis of reports of HBV reactivation in individuals infected with 
both viruses and who were treated with DAAs for HCV [19]. The Pharmacovigilance Risk 
Assessment Committee (PRAC) review covered six DAAs marketed in Europe for treatment 
of chronic HCV infection: daclatasvir (Daklinza®), dasabuvir (Exviera®), the combination of 
SOF and LDV (Harvoni®), simeprevir (Olysio®), sofosbuvir (Sovaldi®), and the combination 
OBV/PTV/r (Viekirax®). Since the start of this review, two other DAAs, the combination SOF 
and VEL (Epclusa®) and the combination EBR and GZR (Zepatier®), have been authorized in 
the European Union. In December 2016, the PRAC has confirmed the risk for hepatitis B virus 
(HBV) reactivation when DAAs are used for treatment of HCV infection. The PRAC recom-
mends that, before starting treatment, all patients should be screened for HBV; patients found 
to be coinfected with HCV and HBV should be monitored and managed according to current 
clinical guidelines. Although the frequency of HBV reactivation appears low, the PRAC rec-
ommends that a warning be included in the prescribing information for these medicines [19].
In September 2016, the American Association for the Study of Liver Diseases and the 
Infectious Diseases Society of America (AASLD/IDSA) issued updated guidelines that advise 
clinicians not to prescribe DAAs to patients with HCV until the patients are screened for HBV, 
all because the societies were hearing about HBV reactivation in coinfected patients treated 
with the drugs. If patients who test positive for HBV warrant treatment, they should begin 
that treatment before or at the same time they start to receive direct-acting antivirals for HCV, 
according to the guidelines.
5.3. DAAs and cancer risk
5.3.1. Evidence pointing to a heightened cancer risk
DAAs do not appear to increase risk for liver cancer in patients with hepatitis C infection and 
cirrhosis, but the drugs could make existing but previously undetected cancers worse and 
harder to treat, according to results from a large-scale prospective study [20]. An interesting but 
unexpected finding of this study depicted that 50% of the individuals who developed a tumor 
early in the course of treatment or just after stopping treatment developed a more aggressive 
type of tumor than what was usually seen in the course of the disease. The researchers hypoth-
esized that HCV replication is halted by DAAs; there are dramatic changes in the immunologic 
and molecular microenvironment in the liver and in tumor suppression mechanisms, which 
could allow or even promote the growth of previously undiagnosed microscopic HCC foci. 
Therefore, it is mandatory that patients treated with DAAs with advanced liver disease con-
tinue to be monitored for HCC. The findings also point to the need for careful pretreatment 
screening and continued monitoring of patients treated with direct-acting antivirals for hepa-
titis C in particular who have advanced fibrosis and are therefore at risk for liver cancer [20].
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An Israeli study also points to an increased risk for malignancy in hepatitis C patients treated 
with DAAs [20]. Findings from the retrospective assessment of 273 consecutive patients 
infected with hepatitis C, some with a history of liver cancer and others without, were 
also reported. A sustained viral response at 12 weeks was achieved by 95% of the patients. 
However, over the next 15 months, 14 patients, or 5% of all participants, developed malig-
nancy. Specifically, there were six cases of de novo HCC, three cases of recurrent HCC, four 
cases of extrahepatic cancer, and one case of intrahepatic cholangiocarcinoma. This study also 
correlates an association between DAA efficacy and malignancies progression with higher 
risk although the exact mechanism of this association is not known. However, the researchers 
assumed that the sudden impairment of the immune system may allow the growth of existing 
preclinical cancer clones [20].
5.3.2. Studies finding no elevated cancer risk
In contrast, investigators saw no increased risk for HCC in patients treated with DAAs in 
a retrospective study of 178 patients with hepatitis C infection and HCC who were candi-
dates for liver transplantation [21]. The research showed that the cumulative incidence of 
recurrence over 1 year was lower in patients treated with DAAs before a diagnosis of HCC 
than in a control group of patients never treated with DAAs. However, when the antivirals 
were administered after a diagnosis of liver cancer, the risk for recurrence was similar in the 
antiviral and control groups, which suggests that prediagnosis antiviral therapy could be 
protective. However, this study was conducted in a different population—liver transplant 
patients on a wait list, where a statistically significant decrease in HCC recurrence (P = .04) 
was noticed when patients were administered with DAAs before a HCC diagnosis. When 
patients had a complete initial response to cancer therapy, DAA use did not significantly 
increase the transplantation wait-list dropout rate. The study results support the use of DAAs 
in patients on the transplant wait list with HCC who have achieved initial response to locore-
gional treatment [21].
A systemic review, meta-analyses, and meta-regression revealed no difference in the risk for 
HCC in patients treated with DAAs and those treated with IFN-based therapy [21]. This study 
conducted in Australia, involving 13,875 people from 26 studies on HCC occurrence and 15 
studies on disease recurrence, explicited other culprits involved in recurrence of HCC fol-
lowing DAAs treatment. In fact, the investigators note other factors could explain the higher 
incidence of cancer. The study analysis showed that the shorter duration of follow-up and 
older age of participants rather than the treatment regimen could be responsible for higher 
incidence of HCC. On meta-regression, DAA therapy was not significantly associated with 
HCC occurrence (relative risk [RR], 0.7; P = .6) or recurrence (RR, 1.4; P = .49) [21].
In a Scottish study, the risk for liver cancer after sustained virologic response was not signifi-
cantly different between patients treated with IFN-free therapy and those treated with IFN-
based therapy [21]. Of the 857 cirrhotic patients treated at one of 12 clinics in Scotland, 32% 
were treated with DAA regimens. During a median follow-up of 1.8 years, fewer patients in 
the interferon-free group than in the interferon group developed HCC (12 vs. 34). Even so, the 
risk was significantly higher in the IFN-free group (incidence rate ratio [IRR], 2.18; P = .03) [21].
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5.3.3. DAAs cut risk of liver cancer
Eradicating hepatitis C with DAA therapy reduces the risk of HCC by 71%, according to results 
of a large observational study [22]. The findings are based on 62,051 patients who underwent 
83,695 antiviral treatment regimens in the VA Puget Sound Health Care System. The data 
included 35,873 IFN-only regimens, 26,178 DAA regimens with or without IFN, and 21,644 
DAA-only regimens. The researchers identified 3271 new cases of liver cancer diagnosed at 
least 180 days after the start of antiviral treatment during an average follow-up of 6.1 years. 
The incidence of liver cancer was highest in patients with cirrhosis who failed treatment (3.25 
per 100 patient-years)—followed by patients with cirrhosis and sustained virologic response, 
or SVR, (1.97), no cirrhosis and treatment failure (0.87), and no cirrhosis and SVR (0.24). In 
multivariable models adjusted for potentially confounding factors, SVR was associated with 
a significantly reduced risk of liver cancer, regardless of whether the antiviral treatment was 
DAA-only (adjusted hazard ratio (aHR), 0.29), DAA with IFN (aHR, 0.48), or IFN-only (aHR, 
0.32). In both cirrhotic and non-cirrhotic patients, the risk of liver cancer was reduced [22].
5.4. Viral resistance
The huge genetic diversity due to poor fidelity of its replication enzyme (i.e., RdRp) and rapid 
replication rate configures HCV genome into 7 distinct GTs, more than 84 subtypes, and even 
exists as a quasispecies in a single-infected patient [2]. The viral genome differs by >30% at GT 
level, >15% at subtypes level, and ˂15% within a specific GT (i.e., quasispecies) in an infected 
individual. This genome variation by nucleotide substitutions/mutations is considered a 
major reason for the origination of pre-existing or treatment-emergent RASs in DAA-treated 
patients [2, 23]. Baseline polymorphism and pre-existing or treatment-emergent RASs are the 
most considerable points to the physicians while deciding to initiate oral IFN-free DAAs for 
hepatitis C treatment in treatment-naive (TN) or treatment-experienced (TE) or treatment-
failure patients [23]. It is a well-established fact that viral mutations make the virus less sus-
ceptible to treatment; and in the case of HCV, it has been proven that monotherapy will result 
in selection of mutations which enhance replication in the presence of a drug. HCV resistance 
occurs when nucleotide substitutions randomly appear throughout the genome with every 
replication cycle. Some nucleotide substitutions by chance intervene to bind specific DAAs to 
their specific protein target [23].
Viral variants with RASs in the presence of DAAs possess a fitness advantage, but in the 
absence of DAAs, most will be outcompeted by a wild-type virus [23, 24]. The viral fitness of 
specific RASs potentially determines whether RASs persist after unsuccessful DAA therapy 
and whether they exist at baseline in TN patients. Interestingly, RASs to different DAA classes 
express markedly different viral fitness. The knowledge of RAS may influence clinical manage-
ment of HCV in terms of alter duration of therapy, to add RBV in specific difficult-to-treat sub-
patient populations and severity of disease (cirrhotic vs. non-cirrhotic) and to choose particular 
DAA regimen for retreatment. Interestingly, some RASs affect the treatment response to all 
members of a specific DAA class, whereas others have variable impact on different DAAs of the 
same class. Meanwhile, the prevalence and effects of RASs vary in different populations (i.e., 
within different HCV GT/subtypes and quasispecies, individual RASs may differ in emergence 
and differently impact SVR rates) and may be more relevant in TE patients and those with 
cirrhosis [23, 24].
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Unfortunately, still there are no clear guidelines for resistance testing. Should it be a universal 
testing of all patients’ pretreatment or selective? As we have seen that SVR rates approach almost 
100% for most HCV-treated patients while administered to most DDA regimens [24], it is dif-
ficult to do for everyone. However, this approach is only applicable to test those patients where 
knowledge of the findings may influence clinical management although which patients are 
those is a big question [23]. AASLD in 2017 recommends NS5A RASs testing for LDV/SOF and 
EBR/GZR combination prior to initiate therapy among GT 1 patients by virus subtype, prior TE, 
and cirrhosis status [23]. For GT 3, RASs detection is recommended for SOF/DCV or SOF/VEL 
combination and both for TE and cirrhotic patients, and if Y93H is present, weight-based RBV is 
added to active regimens. In contrast, current EASL recommendations demonstrate that access 
and affordability to reliable HCV resistance testing are limited, and there is limited consensus on 
the techniques used, data interpretation, and reporting of these detections. Surprisingly, EASL 
does not enforce HCV resistance testing prior to treatment and applies only to TE patients who 
were previously treated with PEG-IFN/RBV, PEG-IFN/RBV/SOF, SOF/RBV, etc. [24].
6. Conclusions
The present is pretty great, and the future is extremely positive after the advent and approval of 
IFN-free DAAs to cure hepatitis C. We will continue to push boundaries and now are at a point 
that we should be able to eradicate hepatitis C with these drugs. The journey started from an 
NS5B inhibitor (sofosbuvir) to develop pan-genotypic regimens that offer new perspectives in 
HCV screening and medicine. One size does not fit all; however, in the case of HCV, we are at 
the edge of brick where a single pill could be effective for all HCV genotype-infected popula-
tions in the near future. Thus new therapies afford public health policy makers great opportuni-
ties but, equally, pose dilemmas too where their cost has sparked much controversy and debate 
over who should get them, and HCC recurrence and HBV reactivation are key obstacles pre-
venting to achieve global goal of HCV elimination. With curative treatment options available 
for patients with HCC and HBV, linkage to care and adherence to screening/surveillance guide-
lines should be clearly warranted for early diagnosis of HCC and HBV. Now, our aim should be 
to stimulate discussion as to how we can capitalize on the opportunities that new therapies will 
bring in terms of their expected population-level impact and engineer our treatment strategies 
accordingly. Overall, the future of HCV therapeutics seems bright and becomes brighter every 
day as treatment combinations continue to be designed, developed, and approved.
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